Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Genes Dev ; 32(2): 165-180, 2018 01 15.
Artículo en Inglés | MEDLINE | ID: mdl-29440260

RESUMEN

Multiple congenital disorders often present complex phenotypes, but how the mutation of individual genetic factors can lead to multiple defects remains poorly understood. In the present study, we used human neuroepithelial (NE) cells and CHARGE patient-derived cells as an in vitro model system to identify the function of chromodomain helicase DNA-binding 7 (CHD7) in NE-neural crest bifurcation, thus revealing an etiological link between the central nervous system (CNS) and craniofacial anomalies observed in CHARGE syndrome. We found that CHD7 is required for epigenetic activation of superenhancers and CNS-specific enhancers, which support the maintenance of the NE and CNS lineage identities. Furthermore, we found that BRN2 and SOX21 are downstream effectors of CHD7, which shapes cellular identities by enhancing a CNS-specific cellular program and indirectly repressing non-CNS-specific cellular programs. Based on our results, CHD7, through its interactions with superenhancer elements, acts as a regulatory hub in the orchestration of the spatiotemporal dynamics of transcription factors to regulate NE and CNS lineage identities.


Asunto(s)
ADN Helicasas/fisiología , Proteínas de Unión al ADN/fisiología , Epigénesis Genética , Células-Madre Neurales/metabolismo , Células Neuroepiteliales/metabolismo , Síndrome CHARGE/genética , Línea Celular , Linaje de la Célula/genética , ADN Helicasas/genética , ADN Helicasas/metabolismo , Proteínas de Unión al ADN/genética , Proteínas de Unión al ADN/metabolismo , Elementos de Facilitación Genéticos , Haploinsuficiencia , Humanos , Cresta Neural/metabolismo , Transcripción Genética
2.
J Pharmacol Exp Ther ; 334(2): 395-401, 2010 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-20484556

RESUMEN

We have investigated the pharmacology of sodium (R)-2-[4-(2,2-dimethyl-1,3-dioxan-5-yl) methoxy-3,5-dimethylpyridin-2-yl]methylsulfinyl-1H-benzimidazol (E3710), a new proton pump inhibitor (PPI), and its effect on gastric acid secretion. E3710 irreversibly inhibited H(+),K(+)-ATPase activity in pig gastric vesicles with an acidic internal environment with an IC(50) of 0.28 microM. Administration of E3710 (0.1, 0.2, 0.4, and 0.8 mg/kg; n = 6) intraduodenally in a gastric fistula model in dogs inhibited histamine-stimulated gastric acid secretion at 0 to 2 and 24 to 26 h after administration with ED(50) values of 0.18 and 0.22 mg/kg, respectively. The inhibition by E3710 was 2.3 times more potent than that of another representative PPI, esomeprazole (0.2, 0.4, 0.8, and 1.6 mg/kg; n = 6) at 0 to 2 h after administration (ED(50) = 0.40 mg/kg) and 2.8 times more potent at 24 to 26 h (ED(50) = 0.71 mg/kg). In the gastric fistula dogs, the intragastric pH was >or=4 for 17% (n = 27) of a 24-h period with vehicle alone, but when E3710 was administered, at 0.2 (n = 4), 0.4 (n = 8), and 0.8 mg/kg (n = 5), the pH was >or=4 for 40, 79, and 88% of a day, respectively. The corresponding values for esomeprazole at 0.8 (n = 4) and 1.6 mg/kg (n = 8) were 55 and 59%, respectively. In a crossover study with vehicle, E3710 at 0.4 mg/kg and esomeprazole at 1.6 mg/kg (n = 6), E3710 increased the intragastric pH to >4 for 82% of a day compared with 61% of a day with esomeprazole. These results show that E3710 is a long-acting inhibitor of gastric acid secretion and a promising novel therapy for acid-related diseases, such as gastroesophageal reflux disease.


Asunto(s)
Bencimidazoles/farmacología , Ácido Gástrico/metabolismo , Inhibidores de la Bomba de Protones/farmacología , Sulfóxidos/farmacología , Animales , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/enzimología , Perros , Esomeprazol/farmacología , Mucosa Gástrica/efectos de los fármacos , Mucosa Gástrica/enzimología , Histamina/farmacología , Concentración de Iones de Hidrógeno , Masculino , Conejos , ATPasa Intercambiadora de Sodio-Potasio/antagonistas & inhibidores , Porcinos
3.
Brain Nerve ; 71(8): 875-883, 2019 Aug.
Artículo en Japonés | MEDLINE | ID: mdl-31346144

RESUMEN

Parkinson's disease (PD), a common neurodegenerative disorder, is characterized by selective degeneration of dopaminergic neurons in the substantia nigra. There is no effective treatment to delay or halt the progression of PD. The establishment of disease models, based on human biology, is therefore important for developing effective disease-modifying therapies. The recent progress of human induced pluripotent stem cell-associated technologies provides an opportunity to understand disease etiology, discover new drugs, and develop novel therapeutic interventions.


Asunto(s)
Células Madre Pluripotentes Inducidas , Enfermedad de Parkinson/patología , Neuronas Dopaminérgicas/patología , Humanos , Modelos Biológicos , Sustancia Negra/patología
4.
Stem Cell Reports ; 11(5): 1171-1184, 2018 11 13.
Artículo en Inglés | MEDLINE | ID: mdl-30344006

RESUMEN

Parkinson disease (PD) is a progressive neurological disease caused by selective degeneration of dopaminergic (DA) neurons in the substantia nigra. Although most cases of PD are sporadic cases, familial PD provides a versatile research model for basic mechanistic insights into the pathogenesis of PD. In this study, we generated DA neurons from PARK2 patient-specific, isogenic PARK2 null and PARK6 patient-specific induced pluripotent stem cells and found that these neurons exhibited more apoptosis and greater susceptibility to rotenone-induced mitochondrial stress. From phenotypic screening with an FDA-approved drug library, one voltage-gated calcium channel antagonist, benidipine, was found to suppress rotenone-induced apoptosis. Furthermore, we demonstrated the dysregulation of calcium homeostasis and increased susceptibility to rotenone-induced stress in PD, which is prevented by T-type calcium channel knockdown or antagonists. These findings suggest that calcium homeostasis in DA neurons might be a useful target for developing new drugs for PD patients.


Asunto(s)
Canales de Calcio Tipo T/metabolismo , Neuronas Dopaminérgicas/patología , Mitocondrias/metabolismo , Estrés Oxidativo , Enfermedad de Parkinson/metabolismo , Enfermedad de Parkinson/patología , Apoptosis/efectos de los fármacos , Calcio/metabolismo , Bloqueadores de los Canales de Calcio/química , Bloqueadores de los Canales de Calcio/farmacología , Línea Celular , Neuronas Dopaminérgicas/metabolismo , Homeostasis/efectos de los fármacos , Humanos , Células Madre Pluripotentes Inducidas , Mitocondrias/efectos de los fármacos , Modelos Biológicos , Proyección Neuronal/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Estrés Oxidativo/efectos de los fármacos , Proteínas Quinasas/metabolismo , Rotenona/toxicidad , Ubiquitina-Proteína Ligasas/metabolismo
5.
J Biomol Screen ; 21(10): 1054-1064, 2016 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-28139961

RESUMEN

Because neurons are difficult to obtain from humans, generating functional neurons from human induced pluripotent stem cells (hiPSCs) is important for establishing physiological or disease-relevant screening systems for drug discovery. To examine the culture conditions leading to efficient differentiation of functional neural cells, we investigated the effects of oxygen stress (2% or 20% O2) and differentiation medium (DMEM/F12:Neurobasal-based [DN] or commercial [PhoenixSongs Biologicals; PS]) on the expression of genes related to neural differentiation, glutamate receptor function, and the formation of networks of neurons differentiated from hiPSCs (201B7) via long-term self-renewing neuroepithelial-like stem (lt-NES) cells. Expression of genes related to neural differentiation occurred more quickly in PS and/or 2% O2 than in DN and/or 20% O2, resulting in high responsiveness of neural cells to glutamate, N-methyl-d-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA), and ( S)-3,5-dihydroxyphenylglycine (an agonist for mGluR1/5), as revealed by calcium imaging assays. NMDA receptors, AMPA receptors, mGluR1, and mGluR5 were functionally validated by using the specific antagonists MK-801, NBQX, JNJ16259685, and 2-methyl-6-(phenylethynyl)-pyridine, respectively. Multielectrode array analysis showed that spontaneous firing occurred earlier in cells cultured in 2% O2 than in 20% O2. Optimization of O2 tension and culture medium for neural differentiation of hiPSCs can efficiently generate physiologically relevant cells for screening systems.


Asunto(s)
Técnicas de Cultivo de Célula/métodos , Diferenciación Celular/efectos de los fármacos , Células Madre Pluripotentes Inducidas/citología , Células-Madre Neurales/citología , Medios de Cultivo Condicionados/farmacología , Maleato de Dizocilpina/química , Humanos , Células Madre Pluripotentes Inducidas/efectos de los fármacos , N-Metilaspartato/química , Células-Madre Neurales/efectos de los fármacos , Neuronas/citología , Neuronas/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Oxígeno/metabolismo , Consumo de Oxígeno/genética
6.
J Biomol Screen ; 20(9): 1074-83, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26245650

RESUMEN

Stem cell research has been progressing rapidly, contributing to regenerative biology and regenerative medicine. In this field, small-molecule compounds affecting stem cell proliferation/differentiation have been explored to understand stem cell biology and support regenerative medicine. In this study, we established a multiparametric screening system to detect bioactive compounds affecting the cell fate of human neural stem/progenitor cells (NSCs/NPCs), using human fetal hippocampal NSCs/NPCs, HIP-009 cells. We examined effects of 410 compounds, which were collected based on mechanisms of action (MOAs) and chemotypes, on HIP-009's cell fate (self-renewal, neuronal and astrocytic differentiation) and morphology by automated multiparametric assays and profiled induced cellular phenotypes. We found that this screening classified compounds with the same MOAs into subgroups according to additional pharmacological effects (e.g., mammalian target of rapamycin complex 1 [mTORC1] inhibitors and mTORC1/mTORC2 dual inhibitors among mTOR inhibitors). Moreover, it identified compounds that have off-target effects under matrix analyses of MOAs and structure similarities (e.g., neurotropic effects of amitriptyline among tri- and tetracyclic compounds). Therefore, this automated, medium-throughput and multiparametric screening system is useful for finding compounds that affect the cell fate of human NSCs/NPCs for supporting regenerative medicine and to fingerprint compounds based on human stem cells' multipotency, leading to understanding of stem cell biology.


Asunto(s)
Diferenciación Celular/efectos de los fármacos , Células-Madre Neurales/efectos de los fármacos , Bioensayo , Línea Celular , Autorrenovación de las Células/efectos de los fármacos , Agonistas de Dopamina/farmacología , Evaluación Preclínica de Medicamentos , Ensayos Analíticos de Alto Rendimiento , Hipocampo/citología , Humanos , Células-Madre Neurales/fisiología , Fenotipo
7.
J Biomol Screen ; 19(8): 1174-84, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-24980597

RESUMEN

The hippocampus is an important brain region that is involved in neurological disorders such as Alzheimer disease, schizophrenia, and epilepsy. Ionotropic glutamate receptors-namely,N-methyl-D-aspartate (NMDA) receptors (NMDARs), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors (AMPARs), and kainic acid (KA) receptors (KARs)-are well known to be involved in these diseases by mediating long-term potentiation, excitotoxicity, or both. To predict the therapeutic efficacy and neuronal toxicity of drug candidates acting on these receptors, physiologically relevant systems for assaying brain region-specific human neural cells are necessary. Here, we characterized the functional differentiation of human fetal hippocampus-derived neural stem/progenitor cells-namely, HIP-009 cells. Calcium rise assay demonstrated that, after a 4-week differentiation, the cells responded to NMDA (EC50= 7.5 ± 0.4 µM; n= 4), AMPA (EC50= 2.5 ± 0.1 µM; n= 3), or KA (EC50= 33.5 ± 1.1 µM; n= 3) in a concentration-dependent manner. An AMPA-evoked calcium rise was observed in the absence of the desensitization inhibitor cyclothiazide. In addition, the calcium rise induced by these agonists was inhibited by antagonists for each receptor-namely, MK-801 for NMDA stimulation (IC50= 0.6 ± 0.1 µM; n= 4) and NBQX for AMPA and KA stimulation (IC50= 0.7 ± 0.1 and 0.7 ± 0.03 µM, respectively; n= 3). The gene expression profile of differentiated HIP-009 cells was distinct from that of undifferentiated cells and closely resembled that of the human adult hippocampus. Our results show that HIP-009 cells are a unique tool for obtaining human hippocampal neural cells and are applicable to systems for assay of ionotropic glutamate receptors as a physiologically relevant in vitro model.


Asunto(s)
Evaluación Preclínica de Medicamentos/métodos , Hipocampo/citología , Células-Madre Neurales/efectos de los fármacos , Receptores Ionotrópicos de Glutamato/metabolismo , Calcio/metabolismo , Diferenciación Celular , Línea Celular , Maleato de Dizocilpina/farmacología , Relación Dosis-Respuesta a Droga , Electrofisiología/métodos , Regulación de la Expresión Génica/efectos de los fármacos , Hipocampo/metabolismo , Humanos , Ácido Kaínico/farmacología , N-Metilaspartato/farmacología , Células-Madre Neurales/metabolismo , Quinoxalinas/farmacología , Receptores Ionotrópicos de Glutamato/análisis , Receptores Ionotrópicos de Glutamato/antagonistas & inhibidores , Ácido alfa-Amino-3-hidroxi-5-metil-4-isoxazol Propiónico/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA